Lexicon Pharmaceuticals will release its third quarter 2026 financial results on November 5, 2026, before the market opens. The company will host a conference call and live webcast at 8:30 a.m. ET to discuss the results and provide a business update. Lexicon focuses on developing treatments for serious cardiometabolic diseases, including hypertrophic cardiomyopathy, type 1 diabetes, and obesity. Investors and interested parties can access the webcast via the company's website, with an archived version available afterward.
Lexicon Pharmaceuticals is set to report its third quarter 2026 financial results on November 5, 2026. For readers following the health sector, here is Pluang's market snapshot as of Oct 29, 2026 18:11 WIB: out of 150 priced US health stocks, 95 rose and 47 fell today. Notable movers include Sana Biotechnology Inc at USD 2.71 with a 3.04% gain and Gilead Sciences, Inc. at USD 163.65 with a 2.80% increase.
The inaugural SportsTech Breakthrough Awards recognized leading companies and technologies advancing sports technology globally. Winners span categories like athlete performance, wearables, AI analytics, fan engagement, and smart stadium solutions, h...
The global Industrial Control System (ICS) Security Market is projected to grow from $17.91 billion in 2026 to $38.48 billion by 2031, at a CAGR of 16.5%. This growth is driven by rising cyberattacks targeting critical infrastructure and the increasi...
AdvantageLumber.com has introduced Sketch-A-Deck, a free online software that simplifies deck design for homeowners and contractors. The tool allows users to draw custom deck layouts, attach them to their homes, and generate build-ready plans with de...
Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...
